Tormen Francesco, Banchelli Federico, Masciale Valentina, Maiorana Antonino, Morandi Uliano, Aramini Beatrice
Division of Thoracic Surgery, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Center of Statistic, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Italy.
Int J Surg Case Rep. 2021 Sep;86:106275. doi: 10.1016/j.ijscr.2021.106275. Epub 2021 Aug 4.
Pleomorphic carcinoma of the lung is a rare malignant epithelial tumor. Due to its rarity, its clinicopathological characteristics are not clear, and there is no defined therapeutic path for this type of tumor.
We retrospectively analyzed the medical and pathological reports of 8 patients who underwent surgical resection for pleomorphic carcinoma between 2007 and 2010.
Eight patients were analyzed (7 males and 1 female, mean age 60). All patients underwent CT scans, and the average diameter of the nodules was 56 mm. Four patients were also investigated with FDG-PET with hypermetabolic activity in all four cases. In four patients, the carcinomatous component was adenocarcinoma (all with sarcomatoid component of spindle cell and giant cell carcinoma), although in two patients, it was squamous cell carcinoma (one with spindle cell and one with giant cell). In the two remaining patients, one showed a non-small cell carcinoma with giant cell carcinoma, and the other was a non-small cell carcinoma and squamous cell carcinoma with spindle and giant cell carcinoma. All cases were treated with surgical resection. Only two patients underwent neoadjuvant chemotherapy. At the time of data analysis, only one patient treated with neoadjuvant chemotherapy was alive.
The prognosis for these patients with a diagnosis of pleomorphic carcinoma undergoing surgery is generally better than those not treated with surgical resection, however the survival remains poor. Although with low number of patients, our research would suggest to consider neoadjuvant chemotherapy an appropriate approach for improving the outcomes before surgery.
肺多形性癌是一种罕见的恶性上皮性肿瘤。由于其罕见性,其临床病理特征尚不明确,且对于这类肿瘤没有明确的治疗路径。
我们回顾性分析了2007年至2010年间8例接受手术切除的肺多形性癌患者的医疗和病理报告。
分析了8例患者(7例男性和1例女性,平均年龄60岁)。所有患者均接受了CT扫描,结节平均直径为56毫米。4例患者还接受了FDG-PET检查,所有4例均有高代谢活性。4例患者的癌性成分是腺癌(均伴有梭形细胞和巨细胞癌的肉瘤样成分),不过2例患者为鳞状细胞癌(1例伴有梭形细胞,1例伴有巨细胞)。其余2例患者中,1例表现为伴有巨细胞癌的非小细胞癌,另1例为伴有梭形和巨细胞癌的非小细胞癌和鳞状细胞癌。所有病例均接受了手术切除。只有2例患者接受了新辅助化疗。在数据分析时,只有1例接受新辅助化疗的患者存活。
这些诊断为肺多形性癌并接受手术的患者的预后总体上优于未接受手术切除的患者,然而生存率仍然很低。尽管患者数量较少,但我们的研究表明,术前考虑新辅助化疗是改善治疗效果的一种合适方法。